Key Takeaways
- Valuation is no longer driven by science alone.
- Commercial readiness can strengthen partnership, financing and acquisition optionality.
- Weak commercial assumptions create valuation risk even when clinical data are strong.
- Boards should connect commercial strategy to enterprise narrative early.
Twenty years ago, biotechnology valuations were driven primarily by scientific innovation and clinical results.
Today, investors ask a broader question: can this therapy succeed commercially?
That shift means commercial strategy influences enterprise value long before the first prescription. Related perspective: choosing the right commercial direction.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
